STATCenter·
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Read at STAT →
Health · 1 sources covering this
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/c0c145d8e0785f13ca1840f0d5ea22d1e43de3cf" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B"></iframe>
